Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nooo ... I am not asking for another reverse split !
It was a provocation to Mr. Maza, because the result has been exactly the opposite of what he expected with the last R / S ... Increasing ie the trading price
Read below :
Sept. 24, 2014
... The Company believes that increasing the trading price of our common stock through a Reverse Stock Split would be the first step toward obtaining a listing on a more established market, thereby providing the Company with a market for its common stock that is more accessible than the OTC PINK, which would increase liquidity and may potentially minimize the spread between the "bid" and "asked" prices quoted by market makers. Further, a superior listing may enhance the Company's access to capital in the future, increase the Company's flexibility in responding to anticipated capital requirements, and strengthen the Company's ability to negotiate with large pharmaceutical companies potentially interested in acquiring our technology...
http://ir.stockpr.com/intellectns/press-releases/detail/984/intellect-neurosciences-inc-issues-letter-to-shareholders
Mr. Maza, we need soon new Reverse Split ... at least 1 to 10 ...
Trading price can only go down, without monthly updates, and without knowing the results of clinical trials.
It is good solution for eliminate all shareholders, old and new !
-------------------------------------------
Sept. 24, 2014
... The Company believes that increasing the trading price of our common stock through a Reverse Stock Split would be the first step toward obtaining a listing on a more established market, thereby providing the Company with a market for its common stock that is more accessible than the OTC PINK, which would increase liquidity and may potentially minimize the spread between the "bid" and "asked" prices quoted by market makers. Further, a superior listing may enhance the Company's access to capital in the future, increase the Company's flexibility in responding to anticipated capital requirements, and strengthen the Company's ability to negotiate with large pharmaceutical companies potentially interested in acquiring our technology...
http://ir.stockpr.com/intellectns/press-releases/detail/984/intellect-neurosciences-inc-issues-letter-to-shareholders
I think nobody is agree with your statement:
"... and ILNS will see over a $ 1 in the near future ..."
I believe that will ILNS as PTBI, from $ 0.22 to $ 10 in one night ...
See graph by 24 to 25 October 2014 !!!
.-
Nobody commented about assignment a job or role to someone...
( … appointing additional qualified personnel …)
What do you think about ?
---------------------------------------------------------------
QUESTION :
When a householder has no job and has money to live his family only four months ... what he plans?
REPLY :
He assumes a housemaid for domestic services!
Right answer ...
---------------------------------------------
From Quarterly Report :
... We anticipate that our existing capital resources will enable us to continue operations for the next four months. If we fail to raise additional capital or obtain substantial cash inflows from existing or potential partners within the next few months, we may be forced to cease operations. We cannot assure you that financing will be available in a timely manner, on favorable terms or at all...
--------------------------------------------
"The next part may sound like a contradiction, or might seem a certainty about shining future expectations ..."
------------------------------------------------
... Our CEO and CFO plans to implement appropriate disclosure controls and procedures to remediate these material weaknesses, including (i) appointing additional qualified personnel to address inadequate segregation of duties and ineffective risk management; (ii) adopting sufficient written policies and procedures for accounting and financial reporting and a whistle blower policy; and (iii) implementing sufficient security and restricted access measures regarding our computer systems and implement a disaster recovery plan...
.-
From Quarterly Report (10-q) on 05/12/2015
http://ih.advfn.com/p.php?pid=nmona&article=66829055
... We anticipate that our existing capital resources will enable us to continue operations for the next four months. If we fail to raise additional capital or obtain substantial cash inflows from existing or potential partners within the next few months, we may be forced to cease operations. We cannot assure you that financing will be available in a timely manner, on favorable terms or at all...
"The next part may sound like a contradiction, or might seem a certainty about future expectations ..."
... Our CEO and CFO plans to implement appropriate disclosure controls and procedures to remediate these material weaknesses, including (i) appointing additional qualified personnel to address inadequate segregation of duties and ineffective risk management; (ii) adopting sufficient written policies and procedures for accounting and financial reporting and a whistle blower policy; and (iii) implementing sufficient security and restricted access measures regarding our computer systems and implement a disaster recovery plan...
.-
About your phrase :
"Elliot is trying and I know he is working on stuff cause he just told me so today what it is who knows but at least he there and trying."
Do you think that Elliot will releases soon an update on this project or he will releases an update on Shire?
.-
Does anyone know some update about bankruptcy or change of Ownership/Company ?
Website DELETED ...
.-
I agree with you, also, I think Ms. Sophie Egholm has been on stand-by until last week.
Surely her appointment was made after that Cerespir received a communication from the FDA.
First step has been made, now we must wait for the official announcement of accelerated approval for CSP-1103 ...
Then, it will need at least 10 days to spread the news everywhere (radio, TV, Internet, ...).
Next, it should check out the merger between Intellect and Cerespir - (if my predictions are correct).
Unfortunately, I cannot predict whether Cerespir will acquire Intellect or vice versa.
Depending on the type of agreement the merger, will depend on whether old shareholders of Intellect will be able to recover the capital invested or not ...
a) Intellect acquires Cerespir and does not issue new shares to investors.
b) Cerespir acquires Intellect and issues new shares, offering 1 new share in exchange for 10 shares held ILNS.
c) Cerespir offers 1 new share for 1 share owned ILNS - only after payment of Shire "milestone" on phase 2 for 622 SHP.
d) ? ? ?
.-
April 30, 2015
CereSpir Incorporation Appoints Sophie Egholm as Chief Operating Officer
... has spent her entire career in the pharmaceutical industry holding increasingly senior management positions based on her excellent track record in Business, Finance and Operations Management, with significant experience in clinical trials for Alzheimer’s disease and related therapeutic areas...
...I am delighted to welcome Sophie as Chief Operating Officer, a role for which she is superbly qualified. Her considerable breadth of experience and extraordinary talents will be invaluable to help grow the company and achieve our business objectives,” said Daniel G. Chain, PhD, CereSpir’s President and Chief Executive Officer.
“I am excited to join CereSpir and very pleased to have this opportunity to help the company succeed in its critically important mission that could benefit of millions of people affected by Alzheimer’s disease and other neurodegenerative conditions,” said Sophie Egholm...
http://www.cerespir.com/cerespir-incorporation-appoints-sophie-egholm-as-chief-operating-officer/
---------------------------------------------------------------
Why just now ?
Did Cerespir know something from FDA ?
.-
And, Cerespir owns CSP-1103 (ex CHF 5074)
https://clinicaltrials.gov/ct2/show/NCT01303744?term=cerespir&rank=4
https://clinicaltrials.gov/ct2/results?term=cerespir&pg=1
---------------------------------------------------------------
Cerespir aims to initiate the first Phase 3 trial in 2015. CSP-1103 has been shown to inhibit brain amyloid beta (Aß) plaque deposition, reduce tau pathology and neuro-inflammation and reverse associated memory deficits in AD transgenic mouse models. Additionally CSP-1103 restores normal microglial function by increasing phagocytosis and decreasing production of pro-inflammatory cytokines.
http://www.cerespir.com/about-csp-1103/csp-1103-overview/
---------------------------------------------------------------
CSP-1103 is a novel, first-in-class, small molecule microglial modulator. In a Phase 2 trial in people with Mild Cognitive Impairment (MCI), CSP-1103 was both well tolerated and appeared to both reduce brain inflammation and result in sustained cognition.
http://www.cerespir.com/our-company/introduction-to-cerespir/
.-
Yes, ILNS owns ANTISENILIN !
---------------------------------------------
ANTISENILIN
Intellect has granted non-exclusive licenses related to its ANTISENILIN patent estate to several global pharmaceutical companies.
The ANTISENILIN technology platform relates to: ...
http://www.intellectns.com/licensed-programs
---------------------------------------------
ANTISENILIN
Patents related to the ANTISENILIN platform have issued in the United States (Patent No. 8173127), Europe (Patent No. 2203301) Australia (Patent No. 743827), China (Patent No. 1177616), Japan (Patent No. 381611), New Zealand (Patent No. 337765) and South Africa (Patent No. 2004/9186). Additional patent applications are pending
http://www.intellectns.com/patent-estate
---------------------------------------------------------
.-
I believe to imminent news of an agreement / merger between Intellect and CereSpir.
The FDA is considering whether to grant approval "Fast Track" on phase 2 to CHF5074 and the transition to phase 3 for confirmation.
This news will be like a volcano erupting without forewarning.
The pps could reach $ 50 per share in 24 hours, without news of Shire, Pfizer and GSK ...
Anyway, FDA is working and soon there will be the answer for CereSpir !
.-
Mr. Nitro,
I believe that no one will be able to answer your questions.
Unfortunately, in recent years:
- No news
- no one knows the name of CEO, and if there exists a CEO
- No one answers at phone
- No one is present in the office
- The website has been overshadowed
- Web domain expires in August
In July 2014, I sent email to big Pharma ROCHE about AVAX. They replied to be interested to buy AVAX or for partnership.
http://www.roche.com/research_and_development/partnering/partnering-what.htm
Last month, I sent a request to CTCA to know the status of two clinical trials (O-vax and M-vax). Unfortunately, they replied in the singular ...:
"Unfortunately, this study is no longer accruing patients."
My question: Which one study ( O-vax or M-vax ) ?
-------------------------------------------------- ------------
If you do not own shares of AVAX, I will suggest you to bet on another horse …
Otherwise, you buy shares AVAX as a lottery ticket !
However, I suggest you contact the "Yahoo's board." There are more investors who follow AVAX:
http://finance.yahoo.com/mb/forumview/?&bn=f9d0c3ff-6279-39aa-bcf0-63d515ff7441
Good luck !
The bounce of dead cat ... !
It is just $ 7 thousand ...
Problem is : why AVAX don't pay $ 10 to Server HOSTICA ?
See: http://www.avax-tech.com/
Expiration : 25-aug-2015
Go to http://www.internic.net
.-
You are right, old shareholders lost 99% of their capital ...
I believe that ILNS is a great opportunity for new shareholders.
They could multiply by 10 or 100 their money ... soon should happen something very important!
Old shareholders could recoup some of their original capital ...
If by the end of June, nothing will happen, I think it will be better to abandon ILNS!
.-
Maybe ILNS is waiting together CereSpir the FDA decision ...
I think the games have done ...
I am surprised that you changed your mind about Dr. Chain and Cerespir !
---------------------------------------------------------------
Last Updated: February 9, 2015
Health Authority:
United States ( Food and Drug Administration )
United States ( Institutional Review Board )
Italy ( Ethics Committee )
https://clinicaltrials.gov/ct2/show/NCT01303744?term=cerespir&rank=5
Changes to NCT01303744 on 2015_02_25
https://clinicaltrials.gov/archive/NCT01303744/2015_02_25/changes
---------------------------------------------------------------
... CereSpir is also talking to various crossover funds with a view to a future IPO ...
( together ILNS ? )
... Cerespir has a list of less than five companies to choose from and will be narrowing down the selection and making a final decision once the company has agreed a final Phase III protocol with the FDA, he said. ...
http://www.cerespir.com/news-publications/in-the-news/
.-
Shire - SHP 622
2015 Pipeline: Our strongest ever
http://www.shire.com/shireplc/en/rd/pipeline
.-
Website - Account Suspended !!
See over link :
http://www.avax-tech.com/
-------------------------------
Possible reasons:
1) nonpayment Website ( I don't believe )
2) failure
3) merger with another Biopharma
4) sale of all patents or sale of AVAX to another Biopharma
5) ? ? ?
I hope not the point 2 ...
.-
Question for Mr. / Mrs. Bingo:
What do you suggest we do now?
Sell off our shares before of Reverse Split or hold our shares?
.-
Shire to announce Full Year 2014 results.
Maybe some updates on SHP622 !
http://www.shire.com/shireplc/en/media/shirenews?id=1063
.-
I meant to say "bad sign" in reference to CEO Maza that does not release updates.
Many shareholders believe that Maza is waiting for a response from Shire for some cash "milestone" about SHP 622 ...
Now, we must think that Mr. Maza is waiting for another event ... I do not know what !!!
.-
I mailed to Shire yesterday about SHP622.
Unfortunately, I received a bad reply ... :
Mail sent yesterday to Shire:
Please, I would like to know if there has been progress from Phase 1 to Phase 2 of SHP622 for Friedreich's Ataxia.
Or, if the studies were suspended / terminated.
I received reply today from Shire:
This program is still in Ph1 studies. We will be in a position to make a decision on whether to progress the program later this year.
Kind regards
Sarah Elton-Farr
Investor Relations Shire
.-
Shire’s CEO Discusses Q4 2013 Results … ( February 13, 2014 )
... And we will complete the Phase 2-a study for VP20629, a potential treatment for Friedreich’s Ataxia, before deciding how to move forward. The Pipeline committee gave deep consideration to all these ViroPharma programs, and I think we demonstrated today …
…read more on Seeking Alpha
http://www.disabilitytoday.co.uk/shire-plc-adr-shpg-news-shires-ceo-discusses-q4-2013-results-seeking-alpha/
.-
Note: ( 3 ) SHP622 is currently in a Phase 1/2 Clinical Trial. ( note 3 is finished )
Then begins note number 4 ... You read note ( 4 ) for SHP616 ... it is not ILNS's drug !!!
http://www.shire.com/shireplc/en/rd/pipeline
---------------------------------------------------
I would like to recall to all shareholders that ViroPharma had conducted a study of Phase 1-b before the merger with Shire.
The Phase 1b studies allows simultaneously expanded on several fronts of Phase 1 and 2 ...
.-
Probably, CEO Maza has been in San Francisco to represent "Immune Pharma" at Biotech Showcase on January 12, 2015 ...
See "Immune Pharma on the list :
http://www.ebdgroup.com/bts/participants/index.php#I
.-
I partially agree with your statements:
" ... Maza is a brutal business man he is trying as the CEO of Intellect to make deals plain and simple. He sure is not working for Chain ... "
1) If I had been ILNS's CEO, I would have presented ILNS on the list at Biotech Showcase.
Then, I would have presented in San Francisco to head-on and not like a dog with his tail down.
2) Therefore, I believe that Maza is not working for Chain, but Maza is working together Chain for one and only goal ...
.-
I explain you better:
Therefore, perhaps CEO Maza did introduce ILNS together another biotech company (for example CereSpir), or Maza has not represented ILNS but another company ...
This means:
1) Maza cannot introduce ILNS without support another company !
2) Maza can introduce ILNS together another biotech company (for example CereSpir) !
3) Maza represent another company ( not ILNS, not CereSpir ) !
I believe in step 2, ie ILNS and CereSpir attended together to answer questions from reporters.
It occurred after the presentation of CereSpir. Therefore Maza represented ILNS while Chain represented CereSpir. Everything for common project / plan ...
These are just my assumptions ... we must wait news from any source that attended the Biotech Showcase ...
Note:
I don't know no one Cerespir board ... CereSpir is not exchanged on no market ...
Please, if you known address of Cerespir board, you write it !
.-
QUESTIONS:
1) Does anyone know the plan released by CereSpir in the 15 minutes spent at Biotech Showcase?
2) Does anyone know if Shire has issued statements on OX1 on January 13, at 33rd Annual J.P. Morgan Healthcare Conference?
.-
You told: A very good thing Maza attended the Biotech Showcase ...
My question is: on behalf of those who, CEO Maza attended the Biotech Showcase?
ILNS is not in the list of participants at Biotech Showcase ...
Therefore, perhaps CEO Maza did introduce ILNS together another biotech company (for example CereSpir), or Maza has not represented ILNS but another company ...
.-
Please, could you be more specific about stay of CEO Maza in San Francisco?
And, if you can say, what is source of your information?
I hope that CEO Maza has been yesterday (January 12) at Biotech Showcase together Dr. Chain ... It means a great news ...
( CereSpir will be reporting on its progress and future plans at Biotech Showcase on January 12, 2015 at 9.30 a.m., Track A – Hearst, Parc 55 Wyndham San Francisco, 4th Floor. )
http://www.ebdgroup.com/bts/index.php
.-
... CereSpir will be reporting on its progress and future plans at Biotech Showcase on January 12, 2015 at 9.30 a.m., Track A – Hearst, Parc 55 Wyndham San Francisco, 4th Floor. ...
http://www.cerespir.com/cerespir-incorporated-appoints-eric-karran-ph-d-as-chairman-of-its-scientific-advisory-board/
.-
It seems that website has been modified with some updates ...
For example:: Licensed Programs, Patent Estate, ...
http://www.intellectns.com/licensed-programs
.-
Stay tuned about Shire's update on January 13:
http://www.shire.com/shireplc/en/media/shirenews?id=1050
.-
I had the same impression by over 2 years.
Now, I believe that large investors (and perhaps even ILNS) want to put off the last remaining small shareholders and they want to buy our shares in exchange for candy ...
I believe that we are left a few dozen small shareholders holding approximately 1 -2 million shares, for a total of about 50 - 100 million shares ...
Insignificant shares at current price, but of great interest for imminent evaluation at least $ 1 per share (without R / S)!
.-
My feeling is different: I believe that Evli has worked for many months especially for CereSpir and less for ILNS.
From words of Dr. Chain one senses will to go on the Nasdaq list ...
I believe that the easiest and quickest way is a merger with Intellect and subsequently an IPO with 6 million shares at $ 10 to 15 per share.
Basically, old shareholders will be able to recover and in some cases double our investment ...
I am not a magician, is only my intuition that suggests to me it!
Time will tell if CereSpir and ILNS will become a great company led by the new CEO Chain ...
.-
What do you think of imminent partnership / merger / IPO with CereSpir?
http://www.cerespir.com/cerespir-considers-partnership-and-finance-options-to-fund-phase-iii-ad-trials-ceo/
.-
Six days, is it coincidence?
( OCTOBER 30 - NOVEMBER 5 )
CereSpir is in active discussions with multiple pharma companies to secure a partnership or financing to run two Phase III trials of its Alzheimer’s disease (AD) drug candidate CSP1103, said CEO Daniel Chain. ....
( Date : NOVEMBER 5, 2014 )
http://www.cerespir.com/cerespir-considers-partnership-and-finance-options-to-fund-phase-iii-ad-trials-ceo/
Proxy Statement - Notice of Shareholders Meeting
( Date : OCTOBER 30, 2014 )
http://ih.advfn.com/p.php?pid=nmona&article=64234054
.-
No word from Shire about SHP622:
10 Dec 2014
Shire R&D Day Profiles Innovative Pipeline Expected to Contribute $3 Billion in Product Sales by 2020
However Shire released data of SHP626 to proceed to Phase 1b :
...
SHP626 (LUM002)
An IND for SHP626 in patients with Non-Alcoholic Steatohepatitis (NASH) has been submitted in November and following FDA permission to proceed we plan to initiate a Phase 1b multiple-dose study in Q1 2015. NASH is a condition characterized by fat deposits in the liver, leading to inflammation and, in a subset of patients, significant fibrosis.
...
This is very strange that they did not talk about SHP622, in fact it was already in phase 1b with Viropharma over a year ago ...
What can we conclude?
Perhaps SHP622 does not work, or should we expect a great news from ILNS!
CEO Maza saves us !!!
http://www.shire.com/shireplc/en/media/shirenews?id=1046
Note: ( 3 ) over SHP622
http://www.shire.com/shireplc/en/rd/pipeline
,.
Shire: about "live webcast" in conjunction with its Research and Development (R&D). Day on Wednesday, December 10, 2014
The Agenda is subject to change – December 1, 2014
http://www.shire.com/shireplc/dlibrary/documents/1rd-day-agenda11214.pdf.
.-